An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
for Oligometastatic Prostate Cancer (OMPC)
40 locations incl. Fayetteville
Sponsor: Novartis Pharmaceuticals
Sex: Male·Age: 18 - 100
Code: NCT05939414·Phase 3·Recruiting·Listed Jul 2023